Does cabergoline administration affect endometrial VEGFR-2 expression in a rat model of ovarian hyperstimulation syndrome?

Figures & data

Figure 1. Control group; (A) Endometrium, endometrial stromal cell (black arrow) (hematoxylin-eosin × 200) (B) Endometrial stromal cell (black arrow); VEGFR-2 immunostained endothelial cell (yellow arrow); VEGFR-2 immunostained epithelial cell (blue arrow); VEGFR-2 immunostained microvessel (red arrow) (× 200).

Figure 2. OHSS-placebo group; (A) Endometrium (hematoxylin-eosin × 200) (B) Endometrial stromal cell (black arrow); VEGFR-2 immunostained microvessel (red arrow) (× 200).

Figure 3. Cabergoline group; (A) Endometrium (hematoxylin-eosin × 200) (B) Endometrial stromal cell (black arrow); VEGFR-2 immunostained microvessel (red arrow) (× 200).

Table 1. A comparison of weight gain, ovarian volume, corpora lutea numbers, and numbers of endometrial VEGFR-2 stained cells between the groups.

	Group 1 (Control)	Group 2 (OHSS-placebo)	Group 3 (Cabergoline)	p
Weight gain (g)	8.42 + 1.13	21.42 + 2.29a	15.85 + 1.67a,b	*0.001
Ovarian volume (mm^3)	1.71 + 0.09	10.00 + 0.89a	7.33 + 1.36a,b	*0.001
Numbers of corpora lutea	–	25.43 + 11.07	32.5 + 21.76	0.465
Numbers of endometrial VEGFR-2 stained cells	342.29 + 33.63	188.43 + 78.22a	138.14 + 22.66a	*0.002

Values are mean ± SD.

VEGFR-2: vascular endothelial growth factor receptor 2.

^* p < 0.05 is significant in group 1 vs groups 2-3, and group 2 vs group 3.

^a Statistically significantly different compared with group 1.

^b Statistically significantly different compared with group 2.